Tag Archives: Direct online Procurement

Chongqing Publicizes August Batch of Listed and Delisted Medical Insurance Drugs – Synchronized Database Removal Set as Appeal Window Opens

Leave a reply

Chongqing, China – 20 Sep 2026 – The Chongqing Municipal Healthcare Security Bureau publicized information on medical insurance drugs newly listed (挂网) and delisted (撤网) on the municipal procurement platform during August 2026, per the city’s drug trading and procurement listing rules. For the delisted products, the Bureau plans to simultaneously remove the relevant drug information from the medical insurance system database – a step that effectively ends reimbursement‑channel recognition of those SKUs. The publicity and online acceptance period runs from 20 to 22 September 2026, with real‑name written appeals accepted until the deadline.

Policy Snapshot

ItemDetail
AgencyChongqing Municipal Healthcare Security Bureau
DocumentPublicity of August 2026 Listed and Delisted Medical Insurance Drug Information
ScopeAnnex 1 – drugs listed (挂网) in Aug 2026; Annex 2 – drugs delisted (撤网) in Aug 2026
Follow‑On ActionDelisted products to be removed synchronously from the medical insurance system database
Publicity Period20–22 Sep 2026
Online Acceptance Period20–22 Sep 2026
Appeal RequirementsReal‑name written appeals with lawful, valid evidence and contact details, in both PDF and Word versions; late filings not accepted
Excluded AppealsThose lacking evidence or unrelated to drug medical insurance payment standards – in principle not accepted
OfficeRoom 615, Chongqing Municipal Healthcare Security Bureau, Zone B4, Mercury Technology Building, No. 5 Huangshan Avenue (Middle Section), Liangjiang New Area
ContactsTel: 023‑88979951 / 023‑88979969; Email: cqsybjyyfwglc@163.com (dedicated to this publicity only)

Listing & Delisting Mechanics

  • Monthly Transparency Cycle: The dual‑annex publicity covers the full August turnover of the platform – both newly listed medical insurance drugs and those withdrawn from listing – giving manufacturers, hospitals, and distributors a monthly checkpoint of catalog changes in one of China’s largest municipalities.
  • Database Synchronization: The planned concurrent deletion of delisted products from the medical insurance system database means the withdrawal is not merely a platform‑level change: reimbursement system recognition is revoked in step, tightening the link between procurement listing status and insurance payment eligibility.
  • Enterprise Responsibilities: The Bureau instructs affected enterprises to promptly coordinate with medical institutions on drug stocking and supply arrangements (药品配备), implying that hospitals should adjust formularies and inventories around the listed and delisted SKUs.
  • Strict Appeal Protocol: Appeals must be real‑name, written, evidence‑backed, and submitted in both PDF and Word formats before the deadline; the dedicated email address accepts only appeals related to this publicity, and filings without evidence or unrelated to medical insurance payment standards will in principle be rejected.

Market Impact & Outlook

  • Reimbursement Channel Discipline: Synchronizing delisting with database removal accelerates the exit of non‑compliant or commercially withdrawn products from Chongqing’s reimbursed drug channel, reinforcing the listing platform as the single source of truth for insurance‑payable drugs.
  • Compliance Clock: With publicity, online acceptance, and the appeal deadline all compressed into the three‑day window of 20–22 September, enterprises disputing a listing or delisting outcome must prepare complete evidence packages essentially in advance.
  • Payment‑Standard Focus: The Bureau’s explicit narrowing of acceptable appeals to matters related to drug medical insurance payment standards signals that challenges on other grounds – commercial, procedural, or otherwise – face a high admissibility bar.
  • Supply‑Chain Coordination: Hospitals and distributors should cross‑check the August annexes against formulary systems to ensure newly listed SKUs are orderable and delisted SKUs are removed from procurement workflows, minimizing dispensing and reimbursement disruptions.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the finalization of August 2026 listing and delisting results, the synchronized removal of delisted drugs from the medical insurance system database, appeal outcomes, and related supply arrangements in Chongqing. Actual results may differ due to risks including appeal handling decisions, evidence sufficiency, and subsequent policy adjustments by the Chongqing Municipal Healthcare Security Bureau.-China Health Reform Pulse

Policy Source: https://ylbzj.cq.gov.cn/zwgk_535/gstz/202609/t20260920_16107566.html

Gansu Screens Ninth Batch of Drug Sunshine Listing Applications – Only 229 of 595 Pass Formal Review as Appeal Window Closes

Leave a reply

Lanzhou, China – 18 Sep 2026 – The Gansu Public Resources Trading Center publicized the formal review results of the ninth batch of new drug sunshine listing applications for 2026, disclosing that of 595 products submitted through the national joint review mechanism (联审通办) and the provincial bidding‑and‑procurement management subsystem as of 10 September 2026, only 229 qualified for platform listing while 366 failed the screening. The publicity period runs 20–22 September 2026, with online appeals due by 24:00 on 22 September 2026.

Policy Snapshot

ItemDetail
AgencyGansu Public Resources Trading Center; supervised by the Gansu Provincial Healthcare Security Bureau
DocumentPublicity of Formal Review Results – Ninth Batch of New Drug Sunshine Listings, 2026
Legal BasisGansu Service Guide for the Drug & Medical Consumables Procurement Management Subsystem (v1.0); Gansu Drug Listing/Delisting Rules
Applications Received595 (national joint review + provincial subsystem, as of 10 Sep 2026)
Passed Formal Review229 (≈ 38.5 % pass rate)
Failed Formal Review366 – itemized in the annexed publicity table (.xls)
Publicity Period20–22 Sep 2026
Appeal Deadline24:00, 22 Sep 2026, online only
ContactsBusiness: 0931‑2909290 / 2909266 / 2909265; Supervision: 0931‑8127609 (Provincial Healthcare Security Bureau)

Review Results & Compliance Requirements

  • Formal Review Outcomes: The 229 qualifying products will proceed to sunshine listing on the provincial platform, subject to completion of the publicity period; the 366 rejected products are listed in the annexed Formal Review Results Publicity Table, giving affected manufacturers a clear, product‑level basis for appeal.
  • Price Declaration Undertakings: Listing prices are self‑declared by enterprises under the good‑faith principle and must not exceed Gansu’s provincial price‑management requirements – placing documentation and pricing integrity squarely on applicants.
  • Cross‑Province Price‑Linkage Rule: If a listed drug’s price is reduced in any other province, the manufacturer must proactively apply for a matching price cut in Gansu within one month – failure to do so triggers suspension of trading qualification, extending the nationwide price‑linkage discipline into Gansu’s procurement channel.
  • Appeals Strictly Online: Objections must be filed via the “Appeal & Query” module under the “New Drug Listing Application” menu of the Gansu National Healthcare Insurance Information Platform procurement subsystem; paper and email submissions are not accepted, and non‑conforming filings will be rejected with any resulting losses borne by the enterprise.

Market Impact & Outlook

  • Selective Gatekeeping: A ≈ 38.5 % pass rate (229 of 595) signals rigorous formal screening in Gansu, reinforcing that completeness and accuracy of submission dossiers – not price alone – determine platform access.
  • National‑Provincial Convergence: The batch combined applications from the national joint review mechanism with the provincial subsystem, reflecting China’s ongoing integration of drug procurement access points across provinces.
  • Pricing Discipline Tightening: The one‑month cross‑province price‑adjustment obligation, backed by trading suspension, aligns Gansu with the hardening nationwide enforcement of external‑reference pricing for listed drugs.
  • Immediate Action Window: With the publicity period and appeal deadline both closing on 22 September 2026, manufacturers among the 366 rejected products face a same‑week turnaround to challenge results or prepare compliant resubmissions in future batches.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding appeal outcomes, listing approvals, price‑adjustment obligations, and trading‑qualification status for drug products in Gansu Province. Actual results may differ due to risks including appeal handling decisions, enterprise remediation progress, and subsequent policy adjustments by the Gansu Public Resources Trading Center and the Provincial Healthcare Security Bureau.-China Health Reform Pulse

Policy Source: https://sjfz.ggzyjy.gansu.gov.cn:19002/#/details-medicine?params=H4sIAAAAAAAAA6tWykxRslIyNLewNDcyNTSyMDc0VaoFAElMeS4WAAAA&pop=true

Hunan Rolls Out 2026 TCM Pricing Governance Results – 10x Anchor‑Price Deadline, Risk Flags, and Listing Suspensions

Leave a reply

Changsha, China – 18 Sep 2026 – The Hunan Provincial Healthcare Security Bureau issued Notice Xiang Yi Bao Zhao Cai Han [2026] No. 114, implementing the results of its 2026 province‑wide price governance campaign for traditional Chinese medicine (TCM) decoction pieces and formula granules. The notice applies price‑risk markings to flagged products, orders manufacturers to cut listed prices exceeding 10 times the anchor price by 17:00 on 24 September 2026, imposes listing suspensions of at least three months on non‑compliant products, and confirms that new listing applications resume on 1 October 2026.

Policy Snapshot

ItemDetail
AgencyHunan Provincial Healthcare Security Bureau (China)
DocumentNotice on Implementing the 2026 Price Governance Results for TCM Decoction Pieces and Formula Granules (Xiang Yi Bao Zhao Cai Han [2026] No. 114)
Legal BasisNotice on Launching Price Governance of Listed Prices for TCM Decoction Pieces and Formula Granules (Xiang Yi Bao Zhao Cai Han [2026] No. 103)
ScopeTCM decoction pieces and formula granules listed on Hunan’s provincial procurement platform
Key Deadline17:00, 24 Sep 2026 – cut listed prices to within 10x the anchor price
SanctionsListing suspension (from 3 months) for missed price cuts, unestablished distribution relationships, or non‑conforming invoice information
Appeal Window3 months from the price‑risk‑flagging date, via the appeal module of the procurement subsystem
Channel ReopeningListing applications and filing‑to‑sunshine‑listing conversions accepted again from 1 Oct 2026
Affected ProductsNot disclosed in the notice body; itemized in five annexed lists

Governance Measures in Detail

  • Price‑Risk Flagging: Products whose manufacturers lowered listed prices within the designated window have been cross‑checked against provincial transaction data and marked with price‑risk flags in the bidding‑and‑procurement subsystem of the Hunan Healthcare Insurance Information Platform. Enterprises may review their flags directly; companies that later cut prices into compliance will have flags adjusted periodically under the stated rules.
  • Anchor‑Price Correction (10x Rule): Listed prices more than 10x the anchor price (10x itself excluded) fall within the correction scope. Manufacturers must reprice by the 24 September deadline; products that miss it – absent a pending complaint or appeal – will be suspended from the platform, while products under active appeal will be disposed of per the appeal handling opinions.
  • Compliance‑Based Suspensions: Separate suspensions (effective from the notice’s publication date, running at least three months) apply to products whose enterprises failed to establish required distribution relationships or whose invoice information remained non‑conforming after self‑inspection. Enterprises that subsequently remediate may apply for listing restoration.
  • Due‑Process Safeguards: A three‑month appeal window via the subsystem’s appeal module preserves a formal challenge path for companies disputing their risk flags.
  • Application Resumption: From 1 October 2026, Hunan resumes accepting new listing applications for TCM decoction pieces and formula granules, as well as conversions from filing to sunshine listing – signaling a return to normal channel operations after the governance round.

Market Impact & Outlook

  • Compliance Crunch: Manufacturers of flagged SKUs face a roughly six‑day repricing window between the notice date and the 24 September deadline – a tight turnaround that will test internal pricing governance at TCM producers selling into Hunan.
  • TCM Price Discipline Trend: The anchor‑price mechanism extends the centralized‑procurement playbook from chemical drugs into the historically fragmented TCM decoction‑pieces and formula‑granules market, where wide price dispersion across provinces has drawn sustained regulatory scrutiny.
  • Supply Continuity Risk: Suspensions of three months or longer could create temporary gaps in affected SKUs at Hunan public medical institutions; hospitals and distributors are advised to review the five annexed lists covering price‑correction products, missing distribution relationships, and invoice non‑conformities.
  • Structural Signal: Pairing enforcement suspensions with a firm 1 October reopening suggests Hunan views this round as a market‑clearing exercise rather than a prolonged freeze, with ongoing periodic flag adjustments keeping price discipline continuous.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory deadlines, appeal outcomes, suspension durations, and the resumption of listing applications for TCM decoction pieces and formula granules in Hunan Province. Actual results may differ due to risks including appeal handling decisions, enterprise remediation progress, and subsequent policy adjustments by the Hunan Provincial Healthcare Security Bureau.-China Health Reform Pulse

Policy Source: http://ybj.hunan.gov.cn/ybj/first113541/firstF/f3113607/202609/t20260918_34067089.html